Globus Medical (NYSE:GMED) and NuVasive (Nasdaq:NUVA) today announced an agreement to combine in an all-stock transaction. The deal values NuVasive at $3.1 billion, with Globus shareholders owning roughly three-fourths of the newly merged company. BTIG analysts raised the question of potential anti-trust challenges for the deal, which would create the second-largest spine tech company behind […]
Nuvasive
Analysts downgrade NuVasive stock
Needham analysts wrote today that they downgraded NuVasive (Nasdaq:NUVA) stock ahead of a potentially slow start to 2023. Analysts Davis Saxon, Mike Matson and Joseph Conway contributed to the Needham report. They switched NuVasive from a “Buy” to a “Hold” rating. The analysts explained their belief that NuVasive’s key launches “could begin to slow” in […]
NuVasive reports mixed Q3 results, reduces guidance
NuVasive (Nasdaq:NUVA) reported third-quarter results that beat on EPS but missed on revenue, reducing its guidance amid macroeconomic headwinds. Investors reacted to yesterday evening’s news by sending NUVA shares down more than 1% to 36.84 apiece in morning trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up […]
Former NuVasive executive takes corner office at LimaCorporate
LimaCorporate announced today that its board of directors appointed former NuVasive executive Massimo Calafiore as its new CEO. Calafiore resigned as NuVasive’s chief commercial officer last month. He also served as an EVP at the orthopedic device company before his departure. Before serving as EVP and CCO, Calafiore oversaw NuVasive’s product marketing and commercial functions. […]
The 10 largest orthopedic device companies in the world
Stryker, Johnson & Johnson’s DePuy Synthes and Zimmer Biomet are the largest orthopedic device companies. With elective procedure numbers rebounding after the darkest days of the COVID-19 pandemic, sales at most of the world’s largest orthopedic device companies increased by double-digit percentages during their most recent fiscal years. Here are the world’s 10 largest orthopedic […]
NuVasive chief commercial officer Massimo Calafiore is stepping down
NuVasive this week announced chief commercial officer Massimo Calafiore is resigning, effective August 31. Upon his resignation, Calafiore’s responsibilities will be reallocated among the executive management team while the company aligns its commercial structure. “On behalf of the NuVasive team, I would like to thank Massimo for his impact on our organization,” CEO Chris Barry […]
Nuvasive lowers EPS guidance after mixed-bag Q2
Nuvasive (Nasdaq:NUVA) reported second-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates. The San Diego–based spine surgery tech company yesterday evening reported losses of $893,000, or 2¢ per share, on sales of $310.5 million for the three months ended June 30, 2022 — versus a profit of $1.799 million, or […]
NuVasive beats The Street in Q1, raises 2022 guidance
NuVasive (Nasdaq:NUVA) shares ticked up today on first-quarter results that came in ahead of the consensus forecast. The San Diego–based spine surgery tech company posted profits of $19.2 million, or 35¢ per share, on sales of $290.8 million for the three months ended March 31, 2022, for a massive bottom-line gain out of the red […]
NuVasive announces positive data for its Simplify cervical disc
NuVasive (Nasdaq:NUVA) today announced data from an FDA investigational device exemption study supporting its Simplify cervical disc. San Diego-based NuVasive’s two-level FDA IDE study data was recently published in the Journal of Neurosurgery: Spine and utilized in the device’s FDA pre-market application for two-level indication approval, which NuVasive received in April 2021. The peer-reviewed publication includes […]
NuVasive reports mixed results in Q4
NuVasive (NASDAQ: NUVA) today reported fourth-quarter results that missed the Wall Street consensus on earnings but beat on revenue. The San Diego–based spine surgery tech company lost $36.7 million, or 71¢ per share, on sales of $302.1 million for the quarter ended Dec. 31, 2021 — versus a profit of $1.7 million, or 3¢ per […]
Nuvasive Attrax Putty wins FDA expanded clearance for use in thoracolumbar interbody procedures
Nuvasive today announced that its Attrax Putty received FDA 510(k) clearance for expanded indications in thoracolumbar interbody spine surgery. Attrax Putty is a synthetic, bioactive and osteoconductive bone void filler that drives bone fusion. San Diego–based Nuvasive designed it with a surface microarchitecture that has an optimized environment for bone formation without added cells or […]
